These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12783637)

  • 1. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
    Lam S
    Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin glargine (Lantus).
    Owens DR; Griffiths S
    Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glargine: a new basal insulin.
    Levien TL; Baker DE; White JR; Campbell RK
    Ann Pharmacother; 2002 Jun; 36(6):1019-27. PubMed ID: 12022906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin analogues in the management of diabetes.
    Vázquez-Carrera M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New methods in insulin treatment].
    Neuwirth G
    Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
    Gerich JE
    Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine: a long-acting insulin for diabetes mellitus.
    Garces K
    Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glargine.
    Campbell RK; White JR; Levien T; Baker D
    Clin Ther; 2001 Dec; 23(12):1938-57; discussion 1923. PubMed ID: 11813930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of insulin glargine.
    Home PD; Ashwell SG
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S57-63. PubMed ID: 12324987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled insulin: Exubera.
    Odegard PS; Capoccia KL
    Ann Pharmacother; 2005 May; 39(5):843-53. PubMed ID: 15827072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.